Baxter International (1BAX) Stock Price & Analysis
1BAX Stock Chart & Stats
- Day’s Range
- EUR 20.11 - EUR 20.29
- 52-Week Range
- EUR 8.00 - EUR 36.00
- Previous Close
- EUR 21.49
- Volume
- N/A
- Average Volume (3M)
- 24
- Market Cap
- EUR 10.65B
- Enterprise Value
- EUR 18.49B
- Total Cash (Recent Filing)
- EUR 1.98B
- Total Debt (Recent Filing)
- EUR 8.81B
- Price to Earnings (P/E)
- ―
- Beta
- 0.92
- Next Earnings
- Feb 18, 2027 (Est.)
- EPS Estimate
- 0.53
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.17%
Bulls Say, Bears Say
Bulls Say
Recurring Clinical-care Demand
Baxter’s mix of disposable consumables, IV solutions and renal-therapy products supports repeat purchasing as patients continue receiving treatment. This recurring clinical-use model can provide durable demand and reduce reliance on occasional capital-equipment purchases.
Broad-based Revenue Growth
Growth across every division and geography indicates that recent improvement is not dependent on a single product or market. Broad participation, combined with raised 2026 organic growth guidance, supports a more durable recovery in Baxter’s revenue base.
Deleveraging Progress
Reducing debt from prior-year levels improves Baxter’s financial resilience and can lower pressure on future cash flows. Continued progress toward approximately three times net leverage would create greater flexibility for investment and other capital-allocation priorities.
Bears Say
Persistent Net Losses
Persistent net losses show that Baxter’s positive EBITDA and revenue recovery have not yet translated into sustainable bottom-line profitability. Until earnings conversion improves, the company has less internally generated capacity to reduce debt, invest, or absorb operating setbacks.
Weak Free-cash-flow Conversion
The sharp decline in operating and free cash flow limits Baxter’s flexibility while meaningful debt remains on the balance sheet. Thin cash conversion can constrain reinvestment and debt reduction, making durable improvement in profitability and working cash generation important.
Round Lake Regulatory Exposure
An unresolved FDA warning letter creates an ongoing operational and compliance burden at a manufacturing facility. Required corrective actions may consume management attention and resources, while any disruption or remediation could weigh on product availability, costs, and margins.
Baxter International News
Baxter International Faces Investor Class Action as Defendants Move to Dismiss Securities Claims Over Novum IQ Pump Disclosures
Baxter International Inc. ($BAX) and five current and former executives have asked a federal court to dismiss a securities class action accusing the company of misleading investors about its Novum
1BAX FAQ
What was Baxter International’s price range in the past 12 months?
What is Baxter International’s market cap?
When is Baxter International’s upcoming earnings report date?
How were Baxter International’s earnings last quarter?
Is Baxter International overvalued?
Does Baxter International pay dividends?
What is Baxter International’s EPS estimate?
How many shares outstanding does Baxter International have?
What happened to Baxter International’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Baxter International?
What is the TipRanks Smart Score and how is it calculated?
Baxter International Stock Smart Score
Company Description
Baxter International
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Andrew Hider
- Employees
- 37,500
- Website
- www.baxter.com
- Address
- One Baxter Parkway, Deerfield, IL, 60015, US
Baxter International (1BAX) Earnings & Revenues
1BAX Company Deck
1BAX Earnings Call
Earnings Call SentimentPositive
The call was broadly constructive and reflected improving execution, strong free cash flow, deleveraging progress, segment growth and raised full-year guidance. Management also highlighted ongoing challenges, including lower adjusted earnings, injectables and cephalosporin-related issues, lower margins, inflation, tariffs and several 2027 headwinds. Highlights significantly outweighed the lowlights, while management acknowledged that further work is required to improve consistency and execution.
View all IT:1BAX earnings summaries1BAX Net sales Breakdown
- 47.13% Medical Products and Therapies
- 27.31% Healthcare Systems and Technologies
- 22.17% Pharmaceuticals
- 3.39% Other
1BAX Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 4 | 13 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 2 | 0 | 10 |
